Angimmune
- Biotech or pharma, therapeutic R&D
Angimmune is a clinical stage biotech seeking commercialization partners and investment for our divalent Anti-CD3 biologic — best-in-class transient T cell lymphodepletion — CAR-T, TIL, kidney transplant, tolerance induction, GVHD, CTCL (Fast Track), PTCL. Superior to CyFlu, rATG, and Alemtuzumab. Targets CD3 expressed on all mature T cells, with no adverse effects to neutrophils & platelets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}